Drug Topics
DECEMBER 3, 2024
The higher burden of neurological symptoms among younger and middle-aged adults translated to worse subjective quality of life, according to a recent study.
STAT
DECEMBER 3, 2024
Robert F. Kennedy Jr. made over $20,000 per week as chairman of Children’s Health Defense before stepping away from the nonprofit in 2023 to run for president, new tax filings show. In April 2023, Kennedy announced his presidential run and left his post as chairman and chief legal counsel of the organization he founded in 2007. Though he only spent three and a half months at Children’s Health Defense last year, he walked away with $326,056 — more than doubling his pay
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
DECEMBER 3, 2024
On the most recent episode of Over the Counter, Steve Callahan, Senior Director of Advisory & Insights at MMIT, talked with us about biosimilars and the Inflation Reduction Act.
STAT
DECEMBER 3, 2024
Swedish pharmaceutical company Orexo will no longer pursue an app for treating depression after many years of struggling to sell it. Orexo announced this week that it will no longer license the product, called Deprexis, from German manufacturer GAIA. The companies have worked together on Deprexis in the United States since 2020 and have deals for two other apps, including Modia, an app that provides psychosocial support to people being treated for opioid addiction.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
DECEMBER 3, 2024
TaQuina Warren, PharmD, owner of Focus Pharmacy in Smyrna, Delaware, discussed her career journey and why pharmacists are so crucial to the interoperability of health care.
Fierce Pharma
DECEMBER 3, 2024
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
DECEMBER 3, 2024
Ian Quigley was employee #13 at AI drug company Recursion until 2021, when he quit and turned the basement of his Utah home into a lab to develop AI models for predicting which proteins small molecule drugs might target — a tool he and co-founder Andrew Blevins found was missing during their time at Recursion. When he was setting up the lab, Quigley ordered an Illumina DNA sequencer that the delivery person had wanted to leave on his porch.
Drug Topics
DECEMBER 3, 2024
A study found that patients with obesity who were diagnosed with type 2 diabetes aged 50 or younger had the highest risk of dementia.
Pharmacy Times
DECEMBER 3, 2024
High-dose vitamin C, when combined with chemotherapy, has shown the potential to double the survival rate of patients with late-stage metastatic pancreatic cancer.
STAT
DECEMBER 3, 2024
As physicians, nothing brightens our faces quite like shutting off our computers. We spend almost two hours of every work day wrestling with the long loading times to view clinical data, the litany of structured data sets we must complete to meet medical billing requirements for innumerable insurance companies, and the nearly endless sea of protected health information we must wade through just to find the piece we need for our patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The Guardian - Pharmaceutical Industry
DECEMBER 3, 2024
Coroner says evidence suggests Thomas Kingston, who was married to Lady Gabriella, had a ‘lack of suicidal intent’ The son-in-law of Prince and Princess Michael of Kent killed himself after suffering adverse side-effects from antidepressants prescribed by a Buckingham Palace doctor, an inquest has found. Thomas Kingston, 45, whose marriage to Lady Gabriella at Windsor Castle in 2019 was attended by the late Queen, died from a self-inflicted wound, the senior coroner for Gloucestershire concluded
Fierce Healthcare
DECEMBER 3, 2024
Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out drug discounts to hospitals. | Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out drug discounts to hospitals.
Pharmacy Times
DECEMBER 3, 2024
Postural orthostatic tachycardia syndrome (POTS) diagnoses have greatly increased following the COVID-19 pandemic.
Drug Topics
DECEMBER 3, 2024
Women with prepregnancy overweight or obesity may be more likely to experience postpartum depression.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
DECEMBER 3, 2024
The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.
Fierce Healthcare
DECEMBER 3, 2024
Risant Health completed its acquisition of Cone Health, bringing the nonprofit health system under its umbrella following the acquisition of Geisinger back in March. | Risant Health completed its acquisition of Cone Health, bringing the nonprofit health system under its umbrella following the acquisition of Geisinger back in March.
pharmaphorum
DECEMBER 3, 2024
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements
PioneerRx
DECEMBER 3, 2024
Your pharmacy is already a trusted healthcare resource in your community, but you don’t have to stop at prescriptions or vaccines. Expanding your pharmacy’s.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
DECEMBER 3, 2024
Tune in to the podcast interview with Dr Sharmeen Roy to learn more about precision dosing and how DoseMe is providing effective and safe treatment for all through personalised dosing solutions.
Pharmacy Times
DECEMBER 3, 2024
Al Carter of the National Association of Boards of Pharmacy speaks on recent initiatives to address workforce burnout and stress among pharmacists.
Fierce Pharma
DECEMBER 3, 2024
Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the last biosimilar in its portfolio, in turn freeing up the company to go a | Coherus has agreed to sell its Neulasta biosimilar Udenyca to Intas Pharmaceuticals for up to $558.4 million. The company plans to use the proceeds from the sale to pay off debt and fuel development opportunities for its branded cancer med Loqtorzi.
STAT
DECEMBER 3, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Lots on the table today about AI-driven drug discovery, including some startups to watch in this space. Also, we’ve updated our obesity drug tracker and we talk about Gilead’s new cancer deal.
Pharmacy Times
DECEMBER 3, 2024
A vast majority of patients achieved a positive clinical response with the combination, with improvements in their ocular condition.
Fierce Healthcare
DECEMBER 3, 2024
CVS Health has announced further leadership appointments as the healthcare giant navigates choppy financial waters. | CVS Health has announced further leadership appointments as the healthcare giant navigates choppy financial waters.
European Pharmaceutical Review
DECEMBER 3, 2024
Novartis Pharmaceuticals Corporation (a subsidiary of Novartis AG), is set to collaborate with PTC Therapeutics to develop the potential first oral disease-modifying therapy for Huntington’s disease. The global license and collaboration agreement is focused on PTC Therapeutics’ PTC518 Huntington’s disease programme. PTC will receive $1.0 billion upfront.
pharmaphorum
DECEMBER 3, 2024
Get to know Jackie Marchington, an expert in IPG Health Medical Communications, through this exclusive interview. Learn about her insights, experiences, and perspectives on the industry.
STAT
DECEMBER 3, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Pharma vs Congress: The latest in telehealth talks Eli Lilly and Pfizer have responded to senators who pressed them to share the details of their online platforms LillyDirect and PfizerForAll , seeking to determine whether the pharma giants are violating the federal anti-kick
pharmaphorum
DECEMBER 3, 2024
Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position
Fierce Pharma
DECEMBER 3, 2024
On the heels of similar deals in the U.S. and the EU, the U.K. is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. | On the heels of similar deals in the U.S. and the European Union, the United Kingdom is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. To prepare for a potential future pandemic, the U.K. has inked an accord with CSL Seqirus to acquire more than 5 million doses of the company’s H5 influenza shot.
Pharmacy Times
DECEMBER 3, 2024
The authors recommend that longer assessments with lengthier interventions should be performed to assess potential benefits.
STAT
DECEMBER 3, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. What a SCOTUS vape decision means for the FDA The Supreme Court heard arguments Monday over the FDA’s decision to block certain flavored vapes from the market.
Pharmacy Times
DECEMBER 3, 2024
As use of injectable medications increases for diabetes and other indications, proper administration is crucial.
STAT
DECEMBER 3, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Did you buy anything fun on Black Friday? Cyber Monday? I ordered a phone case that I’ve wanted for years, even though many, many friends have told me it’s “impractical” and “won’t fit in my pocket.
Expert insights. Personalized for you.
247 
Let's personalize your content